drugset / Trial / NCT00030056
GM-CSF in Patients With Pulmonary Alveolar Proteinosis
RandomizedTreatment
Summary
This is a study to determine the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with pulmonary alveolar proteinosis (PAP).
Timeline
- Start
- 2001-09
- Primary completion
- —
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |